Respiratory drug sales peak in November amid worsening AQI

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previous years. This trend highlights a strong link between pollution and illness. States like Uttar Pradesh and Uttarakhand saw significant sales increases for asthma and COPD treatments. Antihistamine use also climbed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xI32Cmw
via IFTTT

Read More

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to $350 million, grants Dr. Reddy's distribution rights across most global markets, excluding North America, Europe, Japan, and Greater China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnlBJLy
via IFTTT

Read More

ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar Shaw

Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT

Read More

Biocon to make Biocon Biologics a wholly owned subsidiary

Biocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Biocon will acquire remaining stakes through a share swap. The deal values Biocon Biologics at $5.5 billion. This integration aims to streamline operations and enhance strategic focus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CZqtSm5
via IFTTT

Read More

Abbott asks stockists to buy only from authorised suppliers

Spurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized suppliers. The government alerted the Drug Controller General of India about the circulation of fake drugs. The All India Organisation of Chemists and Druggists issued an advisory for safe business practices. This is a serious trade alert.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npGh9NW
via IFTTT

Read More

Lupin gets USFDA nod for multiple sclerosis drug

Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fWTzvcA
via IFTTT

Read More

AI and technology tackling India’s growing stroke crisis: Early detection and prevention take centre stage

India faces a mounting crisis with a 51% rise in stroke cases over the last 30 years, recording 1.25 million new strokes in 2021 alone. Yet only a quarter of Indians have access to stroke-ready hospitals. Doctors at the Medtronic X EconomicTimes.com “Stroke Pe Rok” webinar agreed that creating awareness, improving primary care screening, and leveraging emerging technology must become urgent priorities to save lives and reduce stroke burden in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3K5o8sy
via IFTTT

Read More